Cargando…
Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
SDF-1 and CXCR4 are a chemokine and chemokine receptor pair playing critical roles in tumorigenesis. Overexpression of CXCR4 is a hallmark of many hematological malignancies including acute myeloid leukemia, chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, and generally correlates with a poo...
Autores principales: | Peng, Sheng-Bin, Zhang, Xiaoyi, Paul, Donald, Kays, Lisa M., Ye, Ming, Vaillancourt, Peter, Dowless, Michele, Stancato, Louis F., Stewart, Julie, Uhlik, Mark T., Long, Haiyan, Chu, Shaoyou, Obungu, Victor H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782998/ https://www.ncbi.nlm.nih.gov/pubmed/26954567 http://dx.doi.org/10.1371/journal.pone.0150585 |
Ejemplares similares
-
Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017) -
CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338
por: Pollino, Serena, et al.
Publicado: (2019) -
CXCR4 antagonists in hematologic malignancies: more than just mobilizers?
por: Jo, Deog-Yeon
Publicado: (2011) -
Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4
por: Schwickart, Martin, et al.
Publicado: (2015) -
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
por: O'Hara, Mark H., et al.
Publicado: (2020)